Navigation Links
FDA Approves New Treatment for Advanced Form of Kidney Cancer
Date:10/19/2009

SILVER SPRING, Md., Oct. 19 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today approved Votrient (pazopanib), the sixth drug to be approved for kidney cancer since 2005.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090824/FDALOGO)

Votrient is an oral medication that interferes with angiogenesis, the growth of new blood vessels needed for solid tumors to grow and survive.

Votrient is intended for people with advanced renal cell carcinoma, a type of kidney cancer in which the cancerous cells are found in the lining of very small tubes (tubules) in the kidney. In 2009, approximately 49,000 people were diagnosed with renal cell carcinoma and 11,000 people died from the disease.

"The last five years have seen dramatic improvements in treatment options for patients with kidney cancer. Before 2005, the options available offered only limited effectiveness," said Richard Pazdur, M.D., director, Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research.

The five other drugs approved for kidney cancer and their approval dates are: Sorafenib (December 2005), Sunitinib (January 2006), Temsirolimus (May 2007), Everolimus (March 2009), and Bevacizumab (July 2009).

The safety and effectiveness of Votrient was evaluated in a 435-patient study that examined a patient's progression-free survival - the length of time, following enrollment in the study, before the tumor began growing again or before the patient died. Progression-free survival averaged 9.2 months for patients receiving Votrient compared to 4.2 months for patients who did not receive the drug.

Adverse reactions included diarrhea, high blood pressure, hair color changes, nausea, loss of appetite, vomiting, fatigue, weakness, abdominal pain and headache. Votrient can also cause severe and fatal liver toxicity. Hea
'/>"/>

SOURCE U.S. Food and Drug Administration
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. FDA Approves Elitek(R) (rasburicase) for Management of Plasma Uric Acid Levels in Adults with Leukemia, Lymphoma, and Solid Tumors Receiving Anti-Cancer Therapy
2. FDA Approves Cervarix, GlaxoSmithKlines Cervical Cancer Vaccine
3. U.S. Food and Drug Administration Approves CRESTOR(R) for Use in Pediatric Patients With Heterozygous Familial Hypercholesterolemia
4. Chinese Food and Drug Administration Approves Gabexate Mesylate as Pharmaceutical Raw Material
5. FDA Approves New Indication For Mirena(R) to Treat Heavy Menstrual Bleeding in IUD Users
6. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
7. Video: FDA Approves INVEGA(R) SUSTENNA(TM) for the Acute and Maintenance Treatment of Schizophrenia
8. FDA Approves Tekturna HCT(R) as Initial Treatment in Patients Unlikely to Achieve Their Blood Pressure Goals With a Single Agent
9. FDA Approves ADCIRCA(TM) (Tadalafil) Tablets for the Treatment of Pulmonary Arterial Hypertension
10. FDA Approves Vanda Pharmaceuticals Fanapt(TM) for the Treatment of Schizophrenia
11. FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... , September 19, 2014 ... by Equipment Type (Benchtop, Mobile, Industrial, & Laboratory), ... Technology (Tray-style, Manifold, & Rotary) & Geography - ... MarketsandMarkets, defines and segments the lyophilization market on ... with analyses and projections of the market size ...
(Date:9/19/2014)... and ORLANDO, Fla. , ... supporting Inspire therapy continues to grow, with the publication ... published on-line in Otolaryngology – Head and ... causes a worsening of both objective and subjective measures ... directly attribute Inspire therapy for the reduction in obstructive ...
(Date:9/19/2014)... BALTIMORE and CAMBRIDGE, Mass. ... Diagnostics Inc. (PGDx), a provider of advanced ... Blueprint Medicines , a leader in discovering and ... cancers, today disclosed the first-ever comprehensive genomic study ... and deadly cancer of the female reproductive system, ...
Breaking Medicine Technology:Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 2New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 3New Data shows Reductions in obstructive sleep apnea (OSA) severity and improvement of quality of life with Inspire therapy 4First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 2First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 3First Discovery Of Actionable Genetic Alterations In A Deadly Cancer Reported By Personal Genome Diagnostics And Blueprint Medicines 4
... (Nasdaq: VRUS ) announced today the pricing ... its common stock at an offering price of $46.33 ... selling 2,300,000 shares and the selling stockholders are selling ... deducting the underwriting discount and estimated offering expenses, of ...
... investor meeting held today in New York, NY, Watson ... update on its Global businesses, including a detailed overview ... Global Generics and Global Brands businesses, and an update ... the meeting, the Company provided its preliminary 2011 financial ...
Cached Medicine Technology:Pharmasset Prices Public Offering of Common Stock 2Pharmasset Prices Public Offering of Common Stock 3Watson Presents Outlook for Continued Long Term Growth 2Watson Presents Outlook for Continued Long Term Growth 3Watson Presents Outlook for Continued Long Term Growth 4Watson Presents Outlook for Continued Long Term Growth 5Watson Presents Outlook for Continued Long Term Growth 6Watson Presents Outlook for Continued Long Term Growth 7Watson Presents Outlook for Continued Long Term Growth 8
(Date:9/20/2014)... NY (PRWEB) September 20, 2014 Ticket ... Grande concert tickets. This popular ticket exchange is ... , Ariana Grande is nearing that next step in the ... considered a superstar in the music and entertainment business, but ... released her second straight No. 1 album, will hit the ...
(Date:9/20/2014)... The print component of “Work-Life Balance” is being ... with a circulation of approximately 97,000 copies and ... is distributed nationally through a vast social media ... sites and partner outlets. To explore the digital ... , The publication features an exclusive Mediaplanet interview ...
(Date:9/20/2014)... -- As flu season approaches, the best way to ... flu shot and a checkup, according to an infectious ... vaccinate people against the flu, and also address other ... may provide flu shots for their customers, but they ... medical director of infection prevention and control for the ...
(Date:9/20/2014)... 2014 New PharmaPoint Drug Evaluation ... to 2023?. The asthma market saw very slow ... become saturated with relatively efficacious standard therapies, such ... corticosteroids and long-acting beta-agonists (ICS/LABAs), and leukotriene modifiers, ... However, the launch of seven novel targeted biologic ...
(Date:9/20/2014)... Recently, Best Cheap Hosting USA ... its new website. The new site provides the ... products for customers. Here, people can find a ... decision. Also, it has recommended some excellent web ... of the great web hosting suppliers, InMotion ( ...
Breaking Medicine News(10 mins):Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 2Health News:Ariana Grande Tickets in Chicago/Rosemont, Kansas City, Milwaukee, Saint Paul, Dallas, Houston, San Antonio, Oklahoma City Go On Sale Today 3Health News:Getting ‘Wellthy’: Mediaplanet’s “Work-Life Wellness” campaign puts stock in the personal and economic gains of healthy, vital workplace environments for Canadians 2Health News:Get a Flu Shot During Checkup, Doctor Says 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 2Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 3Health News:Symbicort Asthma Market Forecasts to 2023 - Overview, Efficacy, Safety & SWOT Analysis in New Report Available at LifeScienceIndustryResearch.com 4Health News:Best Cheap Hosting USA Launches Its New Website And Recommends InMotion To Worldwide People 2
... fluid in the ears does not improve speech, hearing or ... two reasons for ear tube surgery -- persistent, severe ear ... otherwise healthy child. Doctors have been concerned that if surgery ... long-term developmental impairment. ,"We were led to the conclusion ...
... companies to drop a historic case in South Africa ... according to leading non-governmental organizations (NGOs). ,The 39 ... legalized use and import of generic medicines free from ... biggest in the world, had challenged the order on ...
... Researchers in the UK say that wound healing in depressed ... These and related reports find a place in the latest ... have direct and indirect effects on the rate of wound ... have been shown to affect the immune system, which may ...
... J. Keefe of Duke University Medical School in Durham, North ... of the Journal of pain. Patients who use religion or ... can reduce their pain and boost their sense of well ... expect that people coping with chronic illness or chronic pain ...
... exercising reduces the risk of heart disease. But almost everyone ... But recent study shows that skinny people are also prone ... important factors in the genesis of various heart ailments. ... Canada, who headed the study, says that heart disease does ...
... which was developed to fight resistant bacteria, is already ... resistance. ,The drug linezolid is used to treat ... the old standby antibiotic vancomycin. The hope has been ... problem of vancomycin-resistant enterococci infections. But in the April ...
Cached Medicine News:Health News:Researchers urge caution in using ear tube surgery 2Health News:Researchers urge caution in using ear tube surgery 3Health News:India to benefit from pharma companies' move 2
Delicate membrane hook/pick with hook on side of instrument for engaging membranes. 20 gauge shaft with balanced titanium handle. Dark finish for reduced glare. Left....
0.5 mm angled tip. Round knurled handle with dull finish. Tip angle: 150 degrees....
0.2 mm, 90o angled tip. Flat smooth handle with polished finish....
Nucleus manipulator facilitates lens rotation during phacoemulsification....
Medicine Products: